RCN1

Across TCGA pan-cancer cohorts, RCN1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RCN1 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RCN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RCN1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

GBM, CCRCC, and LSCC are the cancer types where RCN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.248	0.478	<.001	25	view →
CCRCC	OS	Tertile	All	0.561	1.000	.001	17	view →
LSCC	DFS	Quartile	II,III,IV	0.541	1.000	.003	14	view →
LUAD	DFS	Median	III,IV	0.716	0.332	.011	7	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RCN1–GBM (DFS)

Open the GBM breakdown →